跳到主要內容

很遺憾,我們無法支援你的瀏覽器。如果可以,請升級到新版本,或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更新版本。如果無法升級,而且需要支援,請將你的回饋寄給我們。

我們衷心感謝你對這個新體驗的回饋。告訴我們你的想法

Elsevier
與我們共同出版

Profile

Magdalini Polymenidou

Magdalini Polymenidou

University of Zürich, Switzerland

Magdalini Polymenidou is Associate Professor of Biomedicine at the Department of Quantitative Biomedicine of the University of Zurich (UZH). She is an expert on protein aggregation, prions and prion-like phenomena, as well as RNA-binding proteins. She joined UZH as an Assistant Professor in 2013 and her research team studies the molecular mechanisms of ALS and FTD with focus on the formation and properties of the physiological and pathological states of TDP-43 and FUS. Her team combines structural and biochemical analyses with cellular assays and animal models to identify new therapeutic targets from ALS and FTD. Originally trained as a pharmacist in Aristotle University of Thessaloniki (Greece), she did her PhD on prion diseases in the laboratory of Adriano Aguzzi at the University Hospital of Zurich (Switzerland). As a postdoctoral fellow in the group of Don Cleveland at the University of California in San Diego (USA), she used genome-wide approaches to understand the function of TDP-43 and FUS. Among other honors, she was elected an EMBO member (2025), received the Milken & Tambourine ALS Breakthrough Research Fund (2024), the ERC Consolidator Grant (2022), the NIBR Global Scholars Award (2022), the Franco Regli Prize (2019), the EMBO Young Investigator Award (2018), the Georg-Friedrich Götz Prize (2015), the SNSF Professorship (2013), the HFSP Career Development Award (2013) and the NIH Pathway to Independence Award (2011).